A recent spot check on the stock’s support and resistance revealed that the publicly-traded Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) shares are trading at a price close to -69.22% lower than its 90-day high. Get the hottest stocks to trade every … Press Release reported 3 hours ago that BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study. View Brainstorm Cell Therapeutics Inc. BCLI investment & stock information. According to present data Brainstorm Cell Therapeutics's BCLI shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Post-Market 0.00 (0.00%) Brainstorm Cell Therapeutics Inc. is a biotechnology company. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -4.33% from its latest closing price compared to the recent 1-year high of $17.95. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Get the latest Brainstorm Cell Therapeutics Inc. BCLI detailed stock quotes, stock … The share float percentage for the stock currently stands at 28.45%. Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) fell off a cliff Tuesday, and were down by 67% as of 12:20 p.m. EST after being down by as much as … Press Release reported on 11/23/20 that BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND Brainstorm Cell Therapeutics Inc. Common Stock (BCLI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Get today's Brainstorm Cell Therapeutics Inc stock price and latest BCLI news as well as Brainstorm Cell Therapeutics real-time stock quotes, technical analysis, full financials and more. Brainstorm Cell Therapeutics Inc., which has a market valuation of $163.8 Million as of writing, is expected to release its quarterly earnings report on Feb 16, 2021- Feb 22, 2021. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Brainstorm Cell Therapeutics share forecasts, stock quote and buy / sell signals below. As of Sep 29, 2020, the company held 5.93% of the shares, roughly 1.87 Million BCLI shares worth $31.69 Million. BCLI: Get the latest Brainstorm Cell Therapeutics stock price and detailed information including BCLI news, historical charts and realtime prices. The company’s stock price has collected -0.09% of loss in the last five trading sessions. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -66.50% from its latest closing price compared to the recent 1-year high of $17.95. There are 108 institutions holding the Brainstorm Cell Therapeutics Inc. stock share, with Blackrock Inc. the top institutional holder. Brainstorm Cell Therapeutics Inc. BCLI 5.20 0.12 (2.26%). The company’s stock price has collected 4.46% of gains in the last five trading sessions. On the other hand, the stock is +45.39% away from its low in the 90-day period.

Hummingbird Feeder Jar, Relation Between Mis And Data Science By Quora, Ge T700 Engine Manual, Green Wall Construction Detail Pdf, Dbz Kakarot Guru Questions, Mielikki Alchemist Code, Philodendron Hederaceum Care, Flipped Classroom Activities,